Picard / SynCardia Featured on the Cruxx of MedTech Podcast

Picard Medical (NYSE American: PMI) announced on Jan 13, 2026 the launch of a Cruxx to MedTech podcast series focused on the SynCardia Total Artificial Heart (STAH) and the next‑generation fully implantable Emperor device.

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced on Jan 13, 2026 the launch of a Cruxx to MedTech podcast series focused on the SynCardia Total Artificial Heart (STAH) and the next‑generation fully implantable Emperor device.

The series features a patient survival story and an interview with CEO Patrick NJ Schnegelsberg, who outlines the STAH platform, differentiation versus other approaches, the Company's long‑term vision as an alternative to transplantation, and the commercial opportunity from global donor heart shortages.

The podcast is available for download and streaming on Apple Podcasts, Spotify, Google Podcasts and via Cruxx's website.

Argus Jan 13 session

+4.82% close to close Open Argus

Details

News Market Reaction – PMI

On Jan 13, the day this news came out, PMI closed 4.82% above the previous close.

Data tracked by StockTitan Argus for the Jan 13 session.

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Conference participation

   24h Move

   +10.4%

   Management attendance at JPM week conferences and investor meetings.

2. Jan 06

   Product rollout

   24h Move

   +3.6%

   Rollout of FDA-cleared CPC1 Connector Covers for the STAH system.

3. Dec 30

   Governance/leadership

   24h Move

   -6.4%

   CEO elected to AZBio Board, underscoring ecosystem engagement.

4. Dec 24

   Debt financing

   24h Move

   -1.9%

   Announcement of up to $50M senior secured notes and warrants.

5. Dec 18

   Listing milestone

   24h Move

   +10.3%

   NYSE opening bell event marking public company milestone.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total artificial heart, u.s. fda, health canada, end stage heart failure

4 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

u.s. fda regulatory

"first total artificial heart approved by both the U.S. FDA and Health Canada"

The U.S. FDA is the federal agency that reviews and approves drugs, vaccines, medical devices and food products for safety and effectiveness before they can be sold in the United States. For investors, FDA actions act like a gatekeeper — approvals can open the door to large sales and higher company value, while rejections, delays or safety warnings can sharply cut a product’s market potential and a company’s revenue outlook.

health canada regulatory

"total artificial heart approved by both the U.S. FDA and Health Canada"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

end stage heart failure medical

"impact of the STAH on patients facing end stage heart failure."

End stage heart failure is the point at which the heart can no longer pump enough blood to meet the body's needs despite maximal medical treatment, often requiring advanced interventions such as mechanical pumps, heart transplant, or palliative care. For investors, it signals a high unmet medical need and potential market demand for therapies, devices, or supportive services, similar to a crisis that creates urgent demand for new solutions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TUCSON, Ariz., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced the launch of the Cruxx to MedTech Podcast discussing series exploring the SynCardia Total Artificial Heart (STAH) and the next generation, fully implantable Emperor device through the lens of patients and management.

Anchored by a powerful patient survival story, the series highlights the real-world impact of the STAH on patients facing end stage heart failure. The discussion then turns to SynCardia System’s / Picard Medical’s CEO, Patrick NJ Schnegelsberg who outlines the Company’s STAH platform and its next generation fully implantable Emperor system. Management highlights the clear differentiation of STAH compared to other approaches, the Company’s long-term vision to create a true alternative to heart transplantation, and the significant commercial opportunity driven by the global shortage of donor hearts.

The podcast will be available for download and streaming on all major platforms, including Apple Podcasts, Spotify, and Google Podcasts and available directly on Cruxx’s website here: https://www.thisiscruxx.com/content-hub/

About Cruxx

Cruxx is a medical technology search and capital advisory firm on a mission to place MedTech pioneers in transformative roles that help people live longer. With a focus on critical fields such as cardiovascular, surgical robotics, neurotechnology, AI, and digital health, Cruxx partners with founders, executives, and investors to build leadership teams and accelerate life-changing innovation. For information, visit:  www.thisiscruxx.com

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Picard Medical (PMI) announce on January 13, 2026?

Picard announced a Cruxx to MedTech podcast series about the SynCardia Total Artificial Heart and the next‑generation Emperor device.

Who is featured from Picard Medical on the PMI podcast?

CEO Patrick NJ Schnegelsberg outlines the STAH platform and the fully implantable Emperor system.

What patient content is included in the Picard (PMI) podcast series?

The series is anchored by a powerful patient survival story illustrating real‑world impact of the STAH.

Where can investors and listeners access the Picard (PMI) Cruxx podcast?

The podcast is available on Apple Podcasts, Spotify, Google Podcasts and on Cruxx's website.

What topics about the SynCardia Total Artificial Heart does Picard cover on the podcast?

The podcast covers STAH differentiation, the Emperor next‑generation implantable device, long‑term vision, and donor heart shortage‑driven opportunity.